All Trials

A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic HCC (Child-Pugh A–B7) after ≥1 prior systemic therapy and harboring a WNT-pathway–activating alteration receive ALN-BCAT, an IV siRNA that silences CTNNB1 (β-catenin) via hepatic LNP delivery, as monotherapy or combined with pembrolizumab. Excludes fibrolamellar/sarcomatoid/mixed cholangio-HCC and symptomatic extrahepatic disease; aims to define dose and assess preliminary activity, with the combo exploring β-catenin suppression to enhance PD-1 response.

ClinicalTrials.gov ID: NCT06600321

A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic HCC (Child-Pugh A; BCLC B not LRT-eligible or C) or other advanced solid tumors harboring activating FGFR3/FGFR4 alterations or focal FGF19 amplification; prior FGFR inhibitors allowed in dose-escalation but excluded for FGFR4/pan-FGFR in HCC expansion. Patients receive oral TYRA-430, a reversible, FGFR4/FGFR3-biased tyrosine kinase inhibitor targeting FGF19/FGFR-driven tumors.

ClinicalTrials.gov ID: NCT06915753

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with centrally confirmed GPC3-positive advanced or metastatic solid tumors—emphasizing HCC (BCLC B not eligible for LRT or C, Child-Pugh A, ECOG 0–1)—receive AZD9793 monotherapy given IV or SC after prior therapy (Part A: ≥1 prior line; Part B: ≤1 prior line). AZD9793 is an asymmetric trispecific T-cell engager targeting GPC3 and engaging the TCR and CD8 co-receptor to bias CD8+ activation; exclusions include prior GPC3-targeted therapy and significant autoimmune, cardiac/CNS disease, or active infections.

ClinicalTrials.gov ID: NCT06795022

Safety of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Biliary Tract Cancer Patients With Peritoneal Metastases

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with untreated advanced biliary tract cancer (cholangiocarcinoma or gallbladder) and peritoneal metastases, ECOG 0–1, receive standard gemcitabine/cisplatin plus intraperitoneal nab-paclitaxel delivered via PIPAC at specified cycles. Nab-paclitaxel (albumin-bound paclitaxel; microtubule inhibitor) is aerosolized under pressure laparoscopically to enhance peritoneal penetration, with the study focused on safety and feasibility.

ClinicalTrials.gov ID: NCT05285358

A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic or unresectable HER2‑negative adenocarcinoma of the esophagus/GEJ/stomach (no prior metastatic therapy; ECOG 0–2) receive an alternating doublet sFOLFOXIRI schedule: mFOLFOX6 on odd cycles and FOLFIRI on even cycles every 2 weeks. Optional nivolumab (PD‑1 inhibitor) may be added per label to enhance antitumor activity.

ClinicalTrials.gov ID: NCT05332002

A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic/unresectable solid tumors after standard therapy, with dose expansion in squamous histologies (sqNSCLC with/without NRF2 or CUL3 mutations, HNSCC, ESCC post–platinum and checkpoint inhibitor), receive the investigational KEAP1 activator VVD-130037 orally as monotherapy or combined with docetaxel or paclitaxel. VVD-130037 is a covalent, allosteric molecular glue that enhances KEAP1–CUL3–mediated NRF2 degradation to counter NRF2-driven oncogenesis and taxane resistance; patients with KEAP1 nonsense/frameshift mutations are excluded.

ClinicalTrials.gov ID: NCT05954312

Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic, well-differentiated (WHO grade 1–2), SSTR-positive GEP-NETs limited to liver/lymph nodes and eligible for cytoreductive surgery (R1 intent) receive perioperative 177Lu‑DOTATATE PRRT: two neoadjuvant cycles, surgery, then up to two postoperative cycles based on residual disease by 68Ga‑DOTATATE PET/CT. 177Lu‑DOTATATE is a radiolabeled somatostatin analog targeting SSTR2 to deliver beta-emitting lutetium‑177 to tumor cells; patients must have uniform SSTR expression, Ki‑67 ≤20%, ECOG 0–1, and be on stable octreotide LAR.

ClinicalTrials.gov ID: NCT04609592

Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) With Anti-angiogenesis and Chemotherapy in Advanced Gastric and gastroesophageaL Junction (GEJ) Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic, recurrent, or unresectable gastric or GEJ adenocarcinoma (ECOG 0–1), including those previously treated with anti–PD-1 and with PD-L1 CPS/TPS ≥1 in the randomized cohort, receive pembrolizumab (PD-1 inhibitor) plus ramucirumab (VEGFR2 inhibitor) with paclitaxel (or nab-paclitaxel if hypersensitive), comparing two paclitaxel schedules. Key exclusions include significant cardiovascular/bleeding risks, uncontrolled autoimmune or pulmonary disease, active infections (HBV/HCV/HIV), and significant neuropathy.

ClinicalTrials.gov ID: NCT04069273

A Phase I/Ib Open Label, Single-Arm Study of Cabozantinib in Combination with Enfortumab Vedotin (EV) in the Treatment of Locally Advanced or Metastatic Urothelial Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic urothelial carcinoma after prior PD-1/PD-L1 therapy (and prior platinum or platinum-ineligible), ECOG 0–2, receive enfortumab vedotin (anti–Nectin-4 ADC delivering MMAE) plus cabozantinib (multikinase inhibitor of MET/VEGFR/AXL) until progression/toxicity. Excludes prior EV/MMAE or cabozantinib, significant cardiovascular/GI risks, untreated/unstable CNS disease, and grade ≥2 neuropathy.

ClinicalTrials.gov ID: NCT04878029

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic clear cell RCC (any VHL status) receive oral HC-7366—an activator of the GCN2 integrated stress response pathway—either alone or combined with belzutifan (HIF-2α inhibitor), with combination dose escalation/expansion to define MTD/RP2D. Suitable for patients needing a belzutifan-based regimen or eligible for first- or later-line investigational therapy in ccRCC.

ClinicalTrials.gov ID: NCT06234605